Please assess the completion status of the following clinical trial:

Trial Title: Allogenic Cord Blood Transfusion in Patients With Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis: autistic type disorder (ASD).~* Systemic speech underdevelopment~* The presence of attention deficit hyperactivity disorder as a comorbid state~* Cognitive impairment~Exclusion Criteria:~* organic pathology of the brain according to CT, MRI~* the presence of the following diseases in history: heart failure in the stage of decompensation, stroke in history less than 1 year ago, blood diseases;~* decompensation of chronic and endocrinological diseases;~* acute respiratory viral and bacterial infections, period less than 1 month after the acute phase.~* HIV infection, hepatitis B and C.~* oncological diseases, chemotherapy in the anamnesis;~* tuberculosis.~* Severe form of intellectual disability.~* Cerebral palsy.~* epilepsy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- ASD CB-MNC injection. (Type: EXPERIMENTAL): ASD CB-MNC injection from different donors and standard therapy.
- Standard therapy. (Type: OTHER): Patients with standard therapy as control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).